Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Effectiveness of two COVID-19 vaccines (viral vector and inactivated viral vaccine) against SARS-CoV-2 infection in a cohort of healthcare workers.

Effectiveness of two COVID-19 vaccines (viral vector and inactivated viral vaccine) against SARS-CoV-2 infection in a cohort of healthcare workers. Infection control and hospital epidemiology Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V. D., da Silva Victor, E., Pinho, J. R., Cypriano, A., Vieira, L. W., Polonio, M., Ornelas, R. H., de Oliveira, S. M., Borges Junior, F. A., Shibata, A. R., Schettino, G. d., de Oliveira, K. G., Ferraz Santana, R. A., de Mello Malta, F., Amgarten, D., Boechat, A. L., Trecenti, N. M., Kobayashi, T., Salinas, J. L., Edmond, M. B., Rizzo, L. V. 2022: 1-20

Abstract

OBJECTIVES: We aimed to investigate real-world vaccine effectiveness (VE) for Oxford-AstraZeneca (ChAdOx1) and CoronaVac against laboratory-confirmed COVID-19 infection among healthcare workers (HCWs).METHODS: We conducted a retrospective cohort study among HCWs (aged =18 years) working in a private healthcare system in Brazil between January 1, 2021 and August 3, 2021. To assess VE, we calculated VE=1-RR (rate ratio), with RR determined by adjusting Poisson models with the occurrence of COVID-19 infection as the outcome, and the vaccination status as the main exploratory variable. We used the logarithmic link function and simple models adjusting for sex, age and job types.RESULTS: 13,813 HCWs met the inclusion criteria for this analysis. 6,385 (46.2%) received the CoronaVacvaccine, 5,916 (42.8%) received the ChAdOx1 vaccine, and 1,512 (11.0%) were not vaccinated. Overall, COVID-19 infection cases happened in 6% of unvaccinated HCWs, 3% of HCWs receiving two doses of CoronaVacvaccine, and 0.7% of HCWs receiving two doses of ChAdOx1 vaccine (p-value< 0.001). In the adjusted analyses, the estimated VE was 51.3% for CoronaVac, and 88.1% for ChAdOx1 vaccine. Both vaccines reduced the number of hospitalizations, the length of hospital stay, and the need of mechanical ventilation. Nineteen SARSCoV-2 samples from nineteen HCWs were screened for mutations of interest. Eighteen out of nineteen of those samples were Gamma SARS-CoV-2 variant.CONCLUSIONS: While both COVID-19 vaccines (viral vector and inactivated virus) can significantly prevent COVID-19 infection among HCWs, CoronaVac was much less effective. The COVID-19 vaccines were also effective even against a dominant Gamma variant.

View details for DOI 10.1017/ice.2022.50

View details for PubMedID 35351217